Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06945419
PHASE1

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Sponsor: Eli Lilly and Company

View on ClinicalTrials.gov

Summary

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 10 visits. Participation in Part E will last approximately 7 weeks and may include up to 12 visits.

Official title: A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

216

Start Date

2025-04-23

Completion Date

2026-04

Last Updated

2026-03-27

Healthy Volunteers

Yes

Interventions

DRUG

LY4086940

Administered orally

DRUG

Placebo

Administered orally

DRUG

LY4086940

Administered IV

Locations (5)

Fortrea Clinical Research Unit

Daytona Beach, Florida, United States

Clinical Pharmacology of Miami

Miami, Florida, United States

Fortrea Clinical Research Unit

Dallas, Texas, United States

Endeavor Clinical Trials

San Antonio, Texas, United States

Lilly Centre for Clinical Pharmacology

Singapore, Singapore